Press Release / Media Release
Natco's marketing partner Alvogen first to market generic equivalent to oseltamivir phosphate powder for oral suspension in the USA03-11-2017
03-11-2017
Press Release / Media Release
NATCO records INR 432.2 Crore revenue for the Second Quarter, FY 2017-1802-11-2017
Natco Pharma Q2 profit rises 27% at Rs84 crore
Natco Pharma reports a 27.49% rise in consolidated net profit to Rs84.4 crore for the second quarter ended 30 Sept 2017 as against Rs66.2 crore for the corresponding period of the previous fiscal02-11-2017
Board Meeting To Be Held On 2Nd November, 2017
This is to inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Thursday, the 2nd day of November, 2017 at 11.00 a.m. at the Registered Office of the Company to consider, among other things, the following items of businesses and related matters: 1. Approval of the unaudited financial results, both on standalone and consolidated basis for the quarter and half-year ended 30th September, 2017....25-10-2017
Shareholding for the Period Ended September 30, 2017
Natco Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2017. For more details, kindly Click here10-10-2017
Compliance Certificate For The Period Ended 30Th September, 2017
copy of the certificate enclosed10-10-2017
Statement Of Investor Complaints For The Quarter Ended 30Th September 2017
copy of the Share transfer agents letter enclosed10-10-2017
Press Release / Media Release
NATCO's marketing partner Mylan launches generic Glatiramer Acetate in the U.S. market - both 20 mg/mL and 40 mg/mL versions.05-10-2017